Do you want to read an article? Please log in or register.
Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma
Genitourinary Cancer
Related content
Genitourinary Cancer
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial
J Clin Oncol
Birtle AJ, Jones R, Chester J, Lewis R, Biscombe K, Johnson M, Blacker A, Bryan R, Catto JWF, Choudhury A, Das P, Jagdev S, Powles T, Wagstaff J, Cheung KC, Cafferty F, Hall E
doi: 10.1200/JCO.23.01659
Genitourinary Cancer
Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) with UGN-101, A Mitomycin Reverse Thermal Gel
J Urol
Pierorazio PM, Kleinmann N, Shabsigh A, Hu B, Raman JD, Kaimakliotis H, Sankin A, Singla N, Meads A, Burger B, Raju S, Louie MJ, Chamie K, Weizer A, Schoenberg M, OLYMPUS Study GroupGuilherme Godoy, Seth Lerner, John Gore, Scott Hubosky, Marcus Quek, Joshua M. Stern, Surena F. Matin, Christopher J. Weight, Angela Smith, Jonathan Coleman, Jennifer Linehan, Mitchell R. Humphreys, David Lifshitz, Michael Verni, Robert McLaren, Matthew Nielsen, Douglas Scherr, Raymond Pak
doi: 10.1097/JU.0000000000004331
Genitourinary Cancer
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Cancer Treat Rev
Zhang Y, Chen J, Liu H, Dai J, Zhao J, Zhu S, Zhang X, Liang J, Hu X, Zhao J, Liu Z, Shen P, Sun G, Zeng H
doi: 10.1016/j.ctrv.2024.102787
Lung, Respiratory and Thoracic Cancer
Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis
Cancer Treat Rev
Aburaki R, Fujiwara Y, Chida K, Horita N, Nagasaka M
doi: 10.1016/j.ctrv.2024.102833
Head and Neck Cancer
Response to induction chemotherapy as a prognostic indicator in locally advanced head and neck squamous cell carcinoma
J Cancer Res Clin Oncol
Huwyler F, Giger R, Bill R, Rauch D, Haefliger S
doi: 10.1007/s00432-024-06044-2
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
★ 2
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lancet
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S, KEYNOTE-671 Investigators
doi: 10.1016/S0140-6736(24)01756-2
Genitourinary Cancer
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial
Eur Urol
de Wit R, Vaughn DJ, Fradet Y, Fong L, Climent MA, Necchi A, Petrylak DP, Gerritsen WR, Gurney H, Quinn DI, Culine S, Sternberg CN, Bajorin DF, Choueiri TK, Xu J, Imai K, Homet Moreno B, Bellmunt J, Lee JL
doi: 10.1016/j.eururo.2024.07.015
Breast Cancer
Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting
Int J Cancer
Liu B, Song Y, Xu Y, Sun Q, Zhou Y, Lin Y
doi: 10.1002/ijc.35140
Sarcoma
Pathologic complete response in patients with localized soft tissue sarcoma treated with neoadjuvant therapy and its correlation with clinical outcomes: A systematic review
Cancer Treat Rev
Boulouta A, Kyriazoglou A, Kotsantis I, Economopoulou P, Anastasiou M, Pantazopoulos A, Kyrkasiadou M, Moutafi M, Gavrielatou N, Zazas E, Caglar C, Nixon I, Tolia M, Kavourakis G, Psyrri A
doi: 10.1016/j.ctrv.2024.102820